These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7491720)

  • 1. [Shore-term stimulation with myeloid growth factors expands bone marrow hematopoiesis. A magnetic resonance spectroscopic study].
    Hansen B; Jensen KE; Larsen VA; Johnsen HE; Nielsen H; Karle H; Henriksen O
    Ugeskr Laeger; 1995 Nov; 157(45):6265-9. PubMed ID: 7491720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term myeloid growth factor mediated expansion of bone marrow haemopoiesis studied by localized magnetic resonance proton spectroscopy.
    Jensen KE; Hansen PB; Larsen VA; Johnsen HE; Nielsen H; Karle H; Henriksen O
    Br J Haematol; 1994 Nov; 88(3):465-71. PubMed ID: 7529528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
    Hansen PB; Knudsen H; Gaarsdal E; Jensen L; Ralfkiaer E; Johnsen HE
    Bone Marrow Transplant; 1995 Sep; 16(3):373-9. PubMed ID: 8535309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats.
    Fulton R; Gasper PW; Ogilvie GK; Boone TC; Dornsife RE
    Exp Hematol; 1991 Sep; 19(8):759-67. PubMed ID: 1714401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor.
    Broxmeyer HE; Benninger L; Patel SR; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1994 Jan; 22(1):100-2. PubMed ID: 7506671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Robak T; Krykowski E; Warzocha K
    Arch Immunol Ther Exp (Warsz); 1992; 40(5-6):331-7. PubMed ID: 1340191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM; Gulati SC
    Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined effects of interleukin-11, stem cell factor, and granulocyte colony-stimulating factor on newborn rat hematopoiesis: significant enhancement of the absolute neutrophil count.
    Cairo MS; Plunkett JM; Schendel P; van de Ven C
    Exp Hematol; 1994 Oct; 22(11):1118-23. PubMed ID: 7523164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of GM-/G-CSF prior to bone marrow harvest increases collection of CD34+ cells.
    Slowman S; Danielson C; Graves V; Kotylo P; Broun R; McCarthy L
    Prog Clin Biol Res; 1994; 389():363-9. PubMed ID: 7535443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.